(2) Complement-dependent cytotoxicity (CDC): In vitro studies have shown that rituximab can bind to C1q of the complement so that the complement protein can be fixed on the surface of antibody-coated tumour cells, mediating the complement-dependent cytotoxicity [22]. Here, VTN is linked to neoplasm.